Long sustained response during second-line pembrolizumab plus lenvatinib in a patient with recurrent endometrial carcinoma: a case report

The combination of the immune-checkpoint inhibitor pembrolizumab plus lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, has been approved as standard second-line treatment for patients with recurrent or metastatic endometrial cancer progressed to first-line platinum-based chemotherapy regardless of mismatch repair status and based on the results of the KEYNOTE-775 trial. This article reports on the case of a middle-aged woman with advanced microsatellite stable, p53-mutant endometrial cancer who achieved a meaningful and sustained partial response, with good tolerability, to second-line treatment with pembrolizumab plus lenvatinib. This favourable outcome was compared with efficacy and toxicity data available in the current literature. Pembrolizumab plus lenvatinib can significantly prolong progression-free survival, especially in patients with a negative prognostic molecular profile, who at most can benefit from combining different therapeutic strategies. The heterogeneous treatment-related adverse events landscape should not discourage therapy prescription because most adverse events are easily manageable following simple precautions. This article is part of the <i>New treatment options for advanced endometrial carcinoma</i> Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma.